Media headlines about Ocular Therapeutix (NASDAQ:OCUL) have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocular Therapeutix earned a news impact score of 0.04 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.3850652165975 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Ocular Therapeutix (NASDAQ:OCUL) traded up 0.99% during mid-day trading on Tuesday, reaching $6.10. 144,758 shares of the company were exchanged. The stock’s market capitalization is $177.07 million. Ocular Therapeutix has a 12 month low of $4.04 and a 12 month high of $11.91. The firm has a 50-day moving average price of $8.37 and a 200 day moving average price of $8.77.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.10. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.51 million. Ocular Therapeutix had a negative return on equity of 80.26% and a negative net margin of 2,620.06%. During the same quarter in the prior year, the firm earned ($0.35) EPS. Equities research analysts anticipate that Ocular Therapeutix will post ($2.19) EPS for the current fiscal year.

OCUL has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, May 16th. Morgan Stanley cut shares of Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 price objective for the company. in a report on Friday, June 23rd. HC Wainwright set a $10.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Wednesday, August 2nd. BTIG Research cut shares of Ocular Therapeutix from a “buy” rating to a “neutral” rating in a report on Monday, May 15th. Finally, Cantor Fitzgerald decreased their price objective on shares of Ocular Therapeutix from $35.00 to $21.00 and set an “overweight” rating for the company in a report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $20.11.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Ocular Therapeutix (OCUL) Stock Price” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with's FREE daily email newsletter.